Choreo LLC Invests $106,000 in Haleon plc (NYSE:HLN)

Choreo LLC bought a new position in shares of Haleon plc (NYSE:HLNFree Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,497 shares of the company’s stock, valued at approximately $106,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Patrick M Sweeney & Associates Inc. acquired a new stake in shares of Haleon during the 4th quarter worth about $1,083,000. Wellington Management Group LLP grew its stake in Haleon by 164.6% during the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after buying an additional 8,423,475 shares during the last quarter. Douglas Lane & Associates LLC grew its stake in Haleon by 2.1% during the 1st quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company’s stock worth $71,332,000 after buying an additional 175,082 shares during the last quarter. Capstone Investment Advisors LLC purchased a new position in Haleon during the 1st quarter worth approximately $1,969,000. Finally, Procyon Advisors LLC grew its stake in Haleon by 559.9% during the 1st quarter. Procyon Advisors LLC now owns 131,665 shares of the company’s stock worth $1,118,000 after buying an additional 111,713 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on HLN shares. Argus restated a “buy” rating on shares of Haleon in a research note on Tuesday, March 26th. HSBC began coverage on Haleon in a research note on Wednesday, April 17th. They set a “buy” rating on the stock. Finally, Berenberg Bank began coverage on Haleon in a research note on Wednesday, June 5th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Haleon currently has an average rating of “Moderate Buy”.

Check Out Our Latest Research Report on Haleon

Haleon Stock Performance

Shares of HLN stock opened at $8.49 on Tuesday. The stock has a fifty day moving average price of $8.41 and a 200 day moving average price of $8.36. The stock has a market cap of $38.77 billion, a PE ratio of 28.30, a P/E/G ratio of 2.25 and a beta of 0.24. Haleon plc has a 1 year low of $7.70 and a 1 year high of $8.96. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.73 and a current ratio of 1.04.

Haleon (NYSE:HLNGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. Haleon had a return on equity of 13.17% and a net margin of 9.68%. The company had revenue of $3.70 billion during the quarter, compared to analysts’ expectations of $3.71 billion. Sell-side analysts forecast that Haleon plc will post 0.46 earnings per share for the current fiscal year.

About Haleon

(Free Report)

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

Further Reading

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.